Netscientific Share Discussion Threads

[investordave] 02/2/2023 14:22

At last. A buy!!!

[investordave] 02/2/2023 14:00

Will someone please buy some shares? This is getting ridiculous

[loafofbread] 31/1/2023 13:32

Finally.

A new website and company update from ProAxis on it's way.

7 products on the market.

ProteaseTag Active Neutrophil Elastase Immunoassay (CE Marked)
ProteaseTag Active Proteinase 3 Immunoassay (CE Marked)
ProteaseTag Active Cathepsin G Immunoassay (Research-Use Only)
NEATstik (lateral flow test for active Neutrophil Elastase; CE Marked)
K-POSTn immunoassay (In-licensed from University of Geneva; CE Marked)
Covid-19 serology assay (In-licensed from AstraZeneca; CE Marked)
NE Premium (High-sensitivity Neutrophil Elastase assay; CE Marked)

[loafofbread] 31/1/2023 13:29

The proactive presentation from Jan 28th is up on the proactive website.

Some nice new detail in there.

'trading update in the near future'

[loafofbread] 31/1/2023 13:28

SageTech Medical
@SageTechMedical
·
Jan 30
A fantastic month for SageTech Medical - The official UK launch of our solution for the capture and #recycling of waste volatile #anaesthetic agents and the unveiling of our brand new machine has been a huge success! Thank you to everyone who has supported our journey so far!

Also a great interview with the lead at the RD@E Exeter where it has been tested for the last 2 years.

[loafofbread] 29/1/2023 22:50

Add Cytovale to our list of advancing companies.

We hold 1% and on the books from last year at £0.4M.

Safe to say worth a tad more, now we have an FDA product for sale.

[loafofbread] 29/1/2023 22:44

FDA Clears Cytovale’s® IntelliSep® Sepsis Test, First in a New Class of Emergency Department-Focused Diagnostic Tools

IntelliSep® is the first FDA-cleared diagnostic tool to assess cellular host response to aid in identifying emergency department patients with sepsis and contribute to rapid life-saving decisions

January 18, 2023 09:00 AM Eastern Standard Time
SAN FRANCISCO--(BUSINESS WIRE)--Cytovale®, a medical diagnostics company focused on advancing early detection technologies to diagnose fast-moving and immune-mediated diseases, announced today that its IntelliSep® test has received U.S. Food and Drug Administration (FDA) 510(k) clearance to aid in the early detection of sepsis for the approximately 30 million adult patients with signs and symptoms of infection who present to US emergency departments (ED) each year.

IntelliSep is a groundbreaking diagnostic tool that helps clinicians recognize sepsis and supports critical time-sensitive clinical decisions, providing test results in under 10 minutes. The first in a new class of ED-focused diagnostic tools that assess host response, the test is a simple, fast, and intuitive solution that provides actionable answers directly from a standard blood draw. IntelliSep categorizes patients into three bands according to their probability of sepsis, with Band 1 indicating low probability of sepsis and Band 3 indicating high probability of sepsis. The results may equip providers with a tool to optimize clinical outcomes and empower hospitals to improve resource utilization and achieve operational excellence. IntelliSep may also support hospital efforts to meet guidelines set by the Centers for Medicare & Medicaid Services (CMS) for timely sepsis treatment, known as SEP-1.

Sepsis is the leading cause of death worldwide and is responsible for more than 270,000 deaths every year in the United States—more than opioid overdoses, prostate cancer, and breast cancer combined. 1,2 The condition is the body’s overwhelming life-threatening response to an infection, which triggers a chain reaction and quickly leads to tissue damage, organ failure, and death.1 The risk of death from sepsis increases by as much as 8 percent each hour the condition goes untreated.2 According to the Sepsis Alliance, as many as 80 percent of sepsis deaths could be prevented with rapid diagnosis and treatment—making early detection critical to improving clinical, operational, and financial outcomes.1

“Early detection of sepsis is an invaluable capability for healthcare professionals. Quickly identifying sepsis is critical to saving lives, but until now, we’ve lacked a reliable tool to either recognize the condition or explore alternate diagnoses,” said Hollis O’Neal, MD, Medical Director of Research at Our Lady of the Lake Regional Medical Center, Critical Care Physician at LSU Health Sciences Center, and National Principal Investigator on the multi-center CV-SQuISH-ED study that supported the clearance. “IntelliSep is truly a game changer for sepsis because it provides a unique indicator that gets to the heart of the current sepsis definition, immune dysregulation. The test provides hospital staff with the information needed to identify and treat septic patients efficiently and reduce the financial and health burdens of overtreatment for hospitals and patients.”

The CV-SQuISH-ED study is a multi-center clinical validation study that was completed in early 2022 and is being prepared for publication.3 Data from previously published studies demonstrate the 10-minute test’s potential to aid physicians in rapidly identifying patients at increased risk of sepsis.4

“This clearance is a pivotal step forward in Cytovale’s commitment to early detection technologies to improve health," said Cytovale co-founder and CEO Ajay Shah. "Every minute is crucial in identifying sepsis, and IntelliSep has the potential to transform clinical approaches to sepsis triage and diagnosis and save countless lives."

IntelliSep’s innovative technology, which is run on the Cytovale System, assesses the body’s immune response to an infection using immune cell morphology. By applying pressure to tens of thousands of cells and observing their reaction, IntelliSep can provide valuable new insight related to sepsis. The biophysical properties of white blood cells from septic patients demonstrate distinct changes when subjected to pressure; these changes are captured in images and then characterized using a proprietary algorithm to produce a result.

IntelliSep will be available in the United States in the coming weeks.

About IntelliSep®

Cytovale’s® flagship diagnostic tool, IntelliSep, helps providers recognize sepsis and supports critical time-sensitive clinical decisions through its efficient 10-minute testing period, ease of use, integration into established care processes, and low-cost structure.

IntelliSep is pioneering a new way of quickly and accurately analyzing white blood cells to assess a patient’s probability of sepsis. The test is designed to simply and clearly determine the probability of sepsis using a biomechanical evaluation of white blood cells collected from a standard blood draw.

About Cytovale®

Cytovale is committed to improving human health by pioneering early detection technologies powered by insightful assessment of immune activation. Made up of an extraordinary team of life scientists, engineers, clinicians, and dreamers, Cytovale intends to accelerate the time it takes to get from triage to life-saving therapies. For more information, please visit www.cytovale.com. For updates, follow Cytovale on LinkedIn and Twitter.

[longterm3] 27/1/2023 16:17

I disagree.
Under the previous management, they listed on 16th September 2013 at 160 pence,
peaked at around £2 around June 2015.
2019 and most of 2020 saw the share price well below 10 pence, with a few spikes towards 20 pence along the way.

5th August 2020 saw the new management step in - a 10 for 1 share consolidation and a placing at 65 pence , which is where we find ourselves today.

We have had a further placing in June 2021 at 130 pence.

I am as frustrated at the current share price as everyone else and in loss.

However looking at the Companies we hold, the sizable percentage holdings in many and
the progress these Companies are making I am very happy.

These difficult markets for more speculative, riskier investments will pass.
In a year or so I believe many will be wishing they had been buying this companies shares at these bargain prices.

[investordave] 27/1/2023 15:57

He's a complete and utter waste of space.

[loafofbread] 27/1/2023 09:10

Looks like our boss went down a storm!

Useless comes to mind.

[blakieboy7] 26/1/2023 17:13

Ffs I hadn't realised it dropped today until now

[blakieboy7] 24/1/2023 07:54

I just watched it Loaf. Seems like the perfect solution to a big global problem within hospitals. Plus the waste can be purified and recycled hTtps://www.proactiveinvestors.co.uk/companies/news/1004021/sagetech-medical-device-can-reduce-highly-polluting-hospital-emissions-1004021.html

[loafofbread] 23/1/2023 22:37

7hrs ago.

Excellent Sagetech interview on Proactive.

Our CEO, Iain Menneer, talks to
@proactive_UK
's Thomas Warner about the #environmental damage caused by waste volatile #anaesthetic agents and the #innovative solution that SageTech Medical has developed to capture, recover and #recycle these agents.

[loafofbread] 23/1/2023 09:50

PDSB had a meeting on Friday 20th as per their SEC disclosure.

All a bit of a mystery as to FDA or new partner or major investor!?

Coincidence that we have our first investor talk for 6 months on Thursday.

Probably worth a punt before the US opens.

[blakieboy7] 20/1/2023 15:17

PDSB slide deck- htTps://seekingalpha.com/article/4571216-pds-biotechnology-pdsb-investor-presentation-slideshow

[loafofbread] 19/1/2023 19:17

Anyone going to the Proactive event next Thursday at 6pm?

[loafofbread] 17/1/2023 19:15

Q-Bot appointed by energy solutions provider E.ON to install measures to improve the efficiency of Otterburn homes

12 January 2023

Q-Bot has recently been appointed by energy solutions provider E.ON to install its robotic underfloor insulation in 34 properties in Otterburn in the North of England.



The homes are managed by Karbon Homes, which aims to get these properties close to net zero by installing several energy efficiency measures funded through the Social Housing Decarbonisation Fund wave 1.



Formed in 2017, Karbon Homes is a housing association in the North East of England and Yorkshire, managing almost 30,000 homes. They are focused on delivering good quality homes, excellent service to their customers, and creating a sustainable and friendly environment for their local communities.



Karbon Homes aims to drive the path to net zero homes by installing multiple energy efficiency measures. This will involve ensuring appropriate insulation coverage in lofts and increasing the thickness where required, installing external or cavity wall insulation, solar panels which will generate electricity for customers to use for free, and finally Q-Bot’s underfloor insulation.



Anthony Bell, Karbon’s Assistant Director of Asset and Regeneration said: “With the cost of energy rising fast, our work to improve the efficiency of our homes has never been more important. This significant investment, made possible thanks to support from our local authority partners, will reduce the energy demand from these 90 homes and in turn reduce carbon emissions.”



E.ON is the managing agent on behalf of Karbon Homes, acting as the Principal Contractor. E.ON is an energy provider of energy efficiency measures to social housing associations, local authorities, and private residential customers. The retrofit measures are usually financed through government funding such as the Local Authority Delivery Scheme, Social Housing Decarbonisation Fund and Energy Company Obligation. E.ON plays a key role in the retrofit sector, delivering 11 other similar upgrade schemes across the country.



Dave Newitt, Director of E.ON’s Energy Installation Services division, said: “We work with local authorities and housing associations across the country to improve the energy efficiency and sustainability of people’s homes and we’re delighted to be working with Q-Bot and Karbon Homes to improve the energy efficiency of homes across the Otterburn region.



By working with organisations such as the Karbon Homes, we’re able to utilise existing funding programmes through our Energy Company Obligation, to ensure residents can become more sustainable and benefit from lower energy bills and we can work together to support the UK’s net zero ambition.”



Q-Bot provides a unique method of installing underfloor insulation, fully recognised, and leveraged in the housing sector. Operating from its headquarters in London and with operational bases in Newcastle and Newport, Q-Bot‘s robotic measure is essential in the retrofit pathway to meet energy standard and contribute towards net zero target. Controlled remotely, the robot is inserted in the underfloor void, sprays insulation to the underside of suspended floors, and then verifies that the work has been done correctly. The insulation immediately reduces the heat loss through the floor and stops draughts, ensuring a more efficient home. Q-Bot’s robotic solution delivers an EPC improvement between 2-12 points and saves on average £250/yr on heating bills (verified by Energy Saving Trust, 2022).

Karbon Homes was impressed with Q-Bot’s benefits, offering a straightforward, no hassle and cost-effective solution to reduce their property’s energy demand and carbon footprint. Customers can stay inside their house while the work is being done. Q-Bot’s underfloor insulation will ensure Karbon homes’ customers have a more environmentally friendly and warmer home to live in, without mentioning the impact on their energy bills.



The opportunity to work with Eon on the Karbon Homes and other similar projects represents a significant milestone in Q-Bot’s growth. Eon are involved in roughly 20% of all UK Housing Retrofit Projects, and our close collaboration, which has developed through our early Energy Company Obligation (ECO) funding relationship show an exciting trajectory for our innovative underfloor insulation solution. Leigh Fairbrother, Q-Bot Head of Commercial





Notes to editors:

E.ON is the managing agent on behalf of Karbon Homes, acting as the Principal Contractor. E.ON is an energy provider of energy efficiency measures to social housing associations, local authorities, and private residential customers. The retrofit measures are usually financed through government funding such as the Local Authority Delivery Scheme, Social Housing Decarbonisation Fund and Energy Company Obligation. E.ON plays a key role in the retrofit sector, delivering 11 other similar upgrade schemes across the country.

[loafofbread] 16/1/2023 18:14

Our portfolio company
@FOxBIOSYSTEMS
have closed on a funding round, raising €5.8M in new capital.

Learn more➡️

#biotech #lifesciences #seriesb

[blakieboy7] 16/1/2023 12:59

So frustrating loaf. One step forward, two steps back